Xilio Therapeutics, Inc. (XLO): Nasdaq/NYSE listing notice — Xilio receives Nasdaq bid-price deficiency letter for shares below $1.00

Xilio Therapeutics, Inc.

Notice dated April 4, 2025; stock closed below $1.00 for 30 consecutive business days.
Company has 180 calendar days (until Oct 1, 2025) to regain compliance.
To cure, bid price must close at or above $1.00 for at least 10 consecutive business days.
If not cured, Xilio may transfer to Nasdaq Capital Market for an additional 180-day period.
No immediate effect on listing; company evaluating options to regain compliance.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

Xilio Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5450(a)(1)

Exact text from the filing

April 4, 2025, Xilio Therapeutics, Inc. (the “Company”) received a deficiency letter (the “Notice”) from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market, LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the bid price for the Company’s common stock had closed below $1.00 per share, which is the minimum bid price required to maintain continued listing on the Nasdaq Global Select Market under Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Requirement”). The Notice has no immediate effect on the listing of the Company’s common

View on SEC.gov

19 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Xilio Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-25-004599

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.